ASP Isotopes: Advanced Materials Company Targeting Isotope Production

ASP Isotopes (NASDAQ: ASPI) is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company is initially focused on commercializing Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market, and Carbon-14, the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics. Visit ASPIinfo.com to learn more. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock, deemed earned immediately after the IPO, beginning in August 2022, for 12 months of RedChip investor awareness services. ASPI also agreed to pay RedChip a fifty-thousand dollar fee for a national TV ad campaign scheduled to air weekdays in May 2024. For full disclosure, visit RedChip.com/disclosures.